Novo Nordisk Raises Awareness of Chronic Kidney Disease & Type 2 Diabetes Treatment Option, Ozempic®
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
CNBC on MSN7d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
News-Medical.Net on MSN4d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Fierce Pharma5d
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Managed Healthcare Executive12d
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
Managed Healthcare Executive7d
Rybelsus Reduces Cardiovascular Risk by 14% in New Trial | ACC 2025
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
NBC Los Angeles7d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday ... the cardiovascular rather than kidney benefits of the pill, Gough said. Ozempic is already approved to treat chronic kidney disease in diabetes patients.